Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International, Inc. (SSII) delivers advanced surgical robotics solutions through its SSi Mantra platform and SSi Mudra instruments, focusing on affordable minimally invasive procedures. This news hub provides investors and healthcare professionals with essential updates on the company's financial developments, technological advancements, and global market strategies.
Key resources include earnings reports, regulatory milestone announcements, and partnership disclosures. Track updates on robotic surgery system enhancements, international expansion initiatives, and clinical validation progress. All content is curated to support informed analysis of SSII's position in the medical robotics sector.
Discover official press releases covering product launches, executive appointments, and strategic collaborations. The repository maintains strict compliance with financial disclosure standards, offering neutral reporting on operational achievements and market developments.
Bookmark this page for streamlined access to SS Innovations' latest corporate news. Combine regular visits with portfolio monitoring tools for comprehensive tracking of this innovative surgical robotics provider.
SS Innovations has announced that its SSi Mantra Surgical Robotic System has been used to perform over 100 robotic cardiac surgeries, signaling significant market expansion. The SSi Mantra, featuring a unique fifth arm capability, has been utilized in more than 1000 procedures globally. The company anticipates FDA and CE Mark approvals by early 2025, further enhancing its market position. The global cardiac surgery device market is projected to grow from $17.1 billion in 2023 to $24.9 billion by 2030, while the surgical robotics market is expected to increase from $78.8 billion in 2022 to $188.8 billion by 2032. SS Innovations, through its comprehensive robotic cardiac surgery program, aims to provide less invasive, lower cost, and superior outcomes for patients worldwide.
SS Innovations International, Inc. (SSII) achieved a significant milestone by successfully performing the first infant pyeloplasty using its flagship SSi Mantra Surgical Robotic System. The procedure, led by Dr. Chandra Mohan Vaddi in Hyderabad, India, was a success on a 12-month-old baby. The SSi Mantra is the first surgical system made in India and is cost-effective with regulatory approval in India, Guatemala, and Indonesia. The system has been used in over 1000 surgical procedures across various specialties. SS Innovations is seeking regulatory approval in the US and EU by late 2024 or 2025.
FAQ
What is the current stock price of SS Innovations (SSII)?
What is the market cap of SS Innovations (SSII)?
